Study: Drug given during PCI lowers bleeding risk

10/18/2011 | MedPage Today (free registration)

A trial of more than 8,000 patients led by New York University School of Medicine researchers found bivalirudin administered during PCI saw a decreased bleeding risk compared with the use of heparin or heparin combined with glycoprotein IIb-IIIa inhibitors. Researchers also found no increase in thrombotic or ischemic issues in the 12 months following PCI where bivalirudin was used. The results were published in the journal Circulation: Cardiovascular Interventions.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX